Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sher Karki

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Mabs|February 13, 2010
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functionsGregory L Moore, Hsing Chen, Sher Karki, et al.
Molecular Biology of the Cell|May 15, 2002
PLAC-24 is a cytoplasmic dynein-binding protein that is recruited to sites of cell-cell contactSher Karki, Lee A Ligon, Jamison DeSantis, et al.
Molecular Immunology|November 3, 2006
A molecular immunology approach to antibody humanization and functional optimizationGreg A Lazar, John R Desjarlais, Jonathan Jacinto, et al.
Molecular Cancer Therapeutics|August 30, 2008
Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cellsJohn O Richards, Sher Karki, Greg A Lazar, et al.
Blood|December 26, 2008
The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primatesJonathan Zalevsky, Irene W L Leung, Sher Karki, et al.
Molecular Immunology|August 12, 2008
Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodiesSeung Y Chu, Igor Vostiar, Sher Karki, et al.
Mabs|November 30, 2011
A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigensGregory L Moore, Cristina Bautista, Erik Pong, et al.
Nature Biotechnology|January 19, 2010
Enhanced antibody half-life improves in vivo activityJonathan Zalevsky, Aaron K Chamberlain, Holly M Horton, et al.
Blood|July 10, 2010
Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignanciesHolly M Horton, Matthew J Bernett, Matthias Peipp, et al.
Molecular Cancer Therapeutics|June 29, 2017
Inhibition of Megakaryocyte Differentiation by Antibody-Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced ThrombocytopeniaHui Zhao, Sara Gulesserian, Sathish Kumar Ganesan, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Mabs|February 13, 2010
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functionsGregory L Moore, Hsing Chen, Sher Karki, et al.
Molecular Biology of the Cell|May 15, 2002
PLAC-24 is a cytoplasmic dynein-binding protein that is recruited to sites of cell-cell contactSher Karki, Lee A Ligon, Jamison DeSantis, et al.
Molecular Immunology|November 3, 2006
A molecular immunology approach to antibody humanization and functional optimizationGreg A Lazar, John R Desjarlais, Jonathan Jacinto, et al.
Molecular Cancer Therapeutics|August 30, 2008
Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cellsJohn O Richards, Sher Karki, Greg A Lazar, et al.
Blood|December 26, 2008
The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primatesJonathan Zalevsky, Irene W L Leung, Sher Karki, et al.
Molecular Immunology|August 12, 2008
Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodiesSeung Y Chu, Igor Vostiar, Sher Karki, et al.
Mabs|November 30, 2011
A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigensGregory L Moore, Cristina Bautista, Erik Pong, et al.
Nature Biotechnology|January 19, 2010
Enhanced antibody half-life improves in vivo activityJonathan Zalevsky, Aaron K Chamberlain, Holly M Horton, et al.
Blood|July 10, 2010
Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignanciesHolly M Horton, Matthew J Bernett, Matthias Peipp, et al.
Molecular Cancer Therapeutics|June 29, 2017
Inhibition of Megakaryocyte Differentiation by Antibody-Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced ThrombocytopeniaHui Zhao, Sara Gulesserian, Sathish Kumar Ganesan, et al.
Pageof 2